Sun Pharmaceutical Industries reported a consolidated net profit of ₹1,989 crore for the July‑September quarter (Q2 FY27), a decline of 36% from ₹3,118 crore logged in the same period last year. The decline follows a 12% rise in revenue from operations to ₹16,199 crore, up from ₹14,478 crore in the year‑ago period. The company’s operating profit, or EBITDA, increased 5% to ₹4,743 crore, compared with ₹4,527 crore in Q2 FY26. However, the EBITDA margin contracted to 29.28% from 31.27% in the prior fiscal year.

Total sales for Q2 FY27 reached ₹16,100 crore, marking an 11.8% growth. Global Innovative Medicines sales rose 6.9% to $356 million, representing 21.1% of total sales. The firm invested ₹778.4 crore in research and development, equivalent to 4.8% of sales. India sales were ₹5,552 crore, up 17.3% and accounting for 34.5% of consolidated sales for the quarter. For the first half of the year, sales were ₹11,027 crore, growing 16.6%.

Sun Pharma’s formulation sales in the United States were $455 million, registering an 8.2% decline and accounting for approximately 27% of total consolidated sales. For the first half of FY26, US sales were $882 million. In emerging markets, formulation sales stood at $350 million for Q2 FY27, rising 7.6% and accounting for 20.7% of total consolidated sales. Formulation sales in Rest of World markets were $241 million, up 3.1% and accounted for 14.3% of total consolidated sales for the quarter.

Kirti Ganorkar, Managing Director of Sun Pharma, said the company’s performance was driven by strong momentum in India, Emerging Markets and Rest of World. She added that Ilumya is now approved in the U.S. for the treatment of adults with active psoriatic arthritis. The company filed four ANDAs and received approval for three during the quarter. Sun’s portfolio includes 58 approved NDAs, while 12 NDAs await US FDA approval.

For the first half of FY27, Sun Pharma posted an 11% YoY increase in sales to ₹31,283.6 crore. Global Innovative Medicines sales grew 9.8% to $707 million, accounting for 21.5% of total sales. EBITDA rose 3.8% to ₹9,161.6 crore, with an EBITDA margin of 29.1%. Profit before exceptional items and tax increased 7% to ₹8,731.1 crore. Net profit stood at ₹4,883.3 crore, while adjusted net profit was ₹6,251.5 crore, up 2.2%.

R&D investment for H1 FY27 was ₹1,604.8 crore, equivalent to 5.1% of sales. External API sales increased 14% to ₹489 crore for Q2 FY27, and for the first half, API sales were ₹1,086 crore, up 12%. Following the earnings, Sun Pharma shares traded at ₹1,827.70 on the National Stock Exchange, rising 3.79%. As of October 30, 2026, the company’s market capitalisation was ₹4.40 lakh crore.